Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

BACKGROUND: Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume, symptoms, and survival over placebo and best available therapy in intermediate-2 or high-risk myelofibrosis patients with baseline platelet counts ≥100 × 10(9)/L in phase III studies. The most comm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Talpaz, Moshe, Paquette, Ronald, Afrin, Lawrence, Hamburg, Solomon I, Prchal, Josef T, Jamieson, Katarzyna, Terebelo, Howard R, Ortega, Gregory L, Lyons, Roger M, Tiu, Ramon V, Winton, Elliott F, Natrajan, Kavita, Odenike, Olatoyosi, Claxton, David, Peng, Wei, O’Neill, Peter, Erickson-Viitanen, Susan, Leopold, Lance, Sandor, Victor, Levy, Richard S, Kantarjian, Hagop M, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4176265/
https://ncbi.nlm.nih.gov/pubmed/24283202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-81
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados